Committee photo

Dr. Bob Ryder

Co-opted Website Co-ordinator & Clinical Lead, Nationwide Audits of New Diabetes Therapies

Bob Ryder went to medical school and undertook junior medical and research jobs in South Wales and Sheffield. He has worked as a Consultant Physician with an interest in Diabetes and Endocrinology at City Hospital, Birmingham since 1991. Over the years special interests have included screening for diabetic retinopathy; diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic impotence; clinical use of IT; treating to target; relative risks and benefits of pioglitazone; glycaemic medications with cardiovascular benefit; community diabetes (QIC best primary and/or community initiative in 2014). He runs ABCD website and leads the ABCD nationwide audits of new therapies, including dapagliflozin, canagliflozin, empagliflozin, liraglutide, exenatide qw, IDegLira, degludec, FreeStyle Libre and semaglutide. He is chief investigator for the NIHR supported, multicentre, ABCD Endobarrier studies, “REVISE-Diabesity”, and the “End-OSA” study of Endobarrier in diabetes with Obstructive Sleep Apnoea. Beyond diabetes he is best known for being principle author of the best selling "An Aid to the MRCP Short Cases", the fourth edition of which is the three volume “An Aid to the MRCP PACES”.